GDF-8 분자 정보
Molecule Name
Growth/differentiation factor 8
분자 별명
GDF-8, Myostatin, GDF8, MSTN, Growth,differentiation factor 8
Drug Development Progress
임상 약물 수8
시판 약물 수0
최고 연구 개발 단계NDA/BLA
표적 별명
MSTN，GDF-8，GDF8，Growth Differentiation Factor 8，MSLHP，Myostatin，Growth/Differentiation Factor 8
분자 배경
Growth differentiation factor 8 (GDF8), also known as myostatin, is a unique member of the transforming growth factor-β superfamily that is expressed in human granulosa cells and has important roles in regulating a variety of ovarian functions. GDF8 acts as a negative regulator of skeletal muscle growth and differentiation. In addition to the expression in the musculoskeletal system, GDF8 is also expressed in various tissues, including the reproductive system.
GDF-8 제품 목록
You Have Viewed 0 Of 0 Results
임상 약물 정보
| 영어 이름 | 연구 코드 | 연구 개발 단계 | 회사 | 적응증 | 임상 시험 |
|---|---|---|---|---|---|
| Talditercept alfa | RO-7239361; BMS-986089; RG-6206; BHV-2000 | Phase 3 Clinical | Bristol-Myers Squibb Company | Muscular Atrophy, Spinal; Muscular Dystrophy, Duchenne; Neuromuscular Diseases; Obesity; Overweight | 상세 |
| Emugrobart | GYM-329; RG-6237; RG-70240; RO-7204239 | Phase 3 Clinical | Chugai Pharmaceutical Co Ltd | Diabetes Mellitus, Type 2; Muscular Atrophy, Spinal; Muscular Dystrophy, Facioscapulohumeral; Obesity; Overweight | 상세 |
| Trevogrumab | REGN-1033; REGN1033; SAR-391786; GDF8 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Myositis, Inclusion Body; Obesity; Sarcopenia | 상세 |
| AAV1-FS344 | AAV1-Follistatin; AAV1-FS344 | Phase 2 Clinical | Nationwide Children'S Hospital | Becker muscular dystrophy; Muscular Dystrophy, Duchenne; Myositis, Inclusion Body | 상세 |
| EL-22 | EL-22 | Phase 1 Clinical | Obesity | 상세 | |
| IBIO-600 | IBIO-600 | Phase 1 Clinical | AstralBio Inc | Obesity; Overweight | 상세 |
| Rinvatercept | RKER-065; KER-065 | Phase 1 Clinical | Keros Therapeutics Inc | Neuromuscular Diseases; Obesity | 상세 |
| SRK-439 | SRK-439 | Phase 1 Clinical | Scholar Rock Inc | Heart Diseases; Obesity | 상세 |